PharmaRoth Labs, Inc. announced that the results of a clinical trial he conducted on pre-Diabetic patients. The trial was 12 weeks duration for pre-Diabetics. There were 98 patients involved using Sucanon(R).

The results were tremendously positive in the key metrics used to determine Type II Diabetes. Blood sugar stabilization and decrease of visceral belly fat were accomplished, without any side-effects. This small trial is another confirmation that Sucanon's(R) efficacy and safety are truly unique in the insulin sensitizer category with applicability extended to the pre-Diabetic segment as well.